Skip to main content

Table 3 Change from baseline in fasting ANGPTL3, lipid and lipoprotein levels with treatment

From: Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study

Study parameters

Mean (SD)

Baseline

Week 27

Change from baseline (%)

ANGPTL3 (µg/L)

115.4 (28.0)

53.9 (22.8)

-54.7 (9.8)

Triglycerides (mmol/L)

9.2 (4.9)

3.4 (3.0)

-59.9 (26.3)

Apo C-III (g/L)

0.3 (0.1)

0.1 (0.1)

-50.9 (27.4)

VLDL-C (mmol/L)

2.7 (1.0)

1.3 (0.8)

-53.5 (18.6)

Non-HDL-C (mmol/L)

5.8 (0.6)

4.6 (1.4)

-20.9 (17.7)

Total cholesterol (mmol/L)

6.4 (0.5)

5.3 (1.3)

-17.7 (14.8)

LDL-C (mmol/L)

2.9 (1.0)

3.3 (0.9)

19.2 (16.1)

HDL-C (mmol/L)

0.7 (0.1)

0.7 (0.2)

8.4 (26.0)

Apo B (µmol/L)

2.4 (0.5)

2.5 (0.6)

1.5 (24.0)

Apo B48 (mg/L)

51.1 (5.6)

15.1 (8.9)

-69.2 (19.8)

Free fatty acids (mmol/L)

1.1 (0.8)

0.5 (0.4)

-41.7 (40.6)

  1. ANGPTL3 Angiopoietin like 3, Apo Apolipoprotein, VLDL-C Very-low-density lipoprotein cholesterol, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol